Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Is Pfizer Stock a Buy Now?: https://g.foolcdn.com/editorial/images/756642/gettyimages-904880170.jpg
Is Pfizer Stock a Buy Now?

Stocks have rallied this year, but one of the world's most famous pharma companies didn't join the party. Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine

Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes: https://g.foolcdn.com/editorial/images/756854/stock-crashing.jpg
Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes

As the year comes to an end, it's time to think about which stocks to sell for tax-loss harvesting. One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). The company's shares have

Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes: https://g.foolcdn.com/editorial/images/756854/stock-crashing.jpg
Why I'm Considering Selling Pfizer for Tax-Loss Harvesting Purposes

As the year comes to an end, it's time to think about which stocks to sell for tax-loss harvesting. One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). The company's shares have

2 Dividend Stocks to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/756237/physician-giving-a-high-five-to-a-young-patient.jpg
2 Dividend Stocks to Buy and Hold Forever

Over long periods, dividend stocks tend to outperform their non-dividend-paying counterparts. There are likely several reasons for this, one of which is that sustaining a dividend program requires a

Is Novavax Stock a Buy Now?: https://g.foolcdn.com/editorial/images/756002/person-getting-vaccinated.jpg
Is Novavax Stock a Buy Now?

Biotech company Novavax (NASDAQ: NVAX) went from being relatively unknown just four years ago to becoming one of the U.S. COVID-19 vaccine market leaders. The company has faced many trials and

Why Pfizer Stock Is Sinking Today: https://g.foolcdn.com/editorial/images/756798/scientist-with-head-down.jpg
Why Pfizer Stock Is Sinking Today

Shares of Pfizer (NYSE: PFE) were sinking 4.4% lower as of 11:10 a.m. ET on Friday after falling as much as 7.1% earlier in the morning. The sell-off came after the company announced that it's

Why Pfizer Stock Is Sinking Today: https://g.foolcdn.com/editorial/images/756798/scientist-with-head-down.jpg
Why Pfizer Stock Is Sinking Today

Shares of Pfizer (NYSE: PFE) were sinking 4.4% lower as of 11:10 a.m. ET on Friday after falling as much as 7.1% earlier in the morning. The sell-off came after the company announced that it's

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?: https://g.foolcdn.com/editorial/images/756214/patient-sitting-on-hospital-bed.jpg
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. That's because they have been partnering to develop a

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?: https://g.foolcdn.com/editorial/images/756214/patient-sitting-on-hospital-bed.jpg
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. That's because they have been partnering to develop a

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?: https://g.foolcdn.com/editorial/images/756214/patient-sitting-on-hospital-bed.jpg
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Biotech companies CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX) are often mentioned in the same sentence. That's because they have been partnering to develop a

Why Abbvie Stock Popped Today: https://g.foolcdn.com/editorial/images/756715/medical-professional-holding-dollar-sign-paperweight.jpg
Why Abbvie Stock Popped Today

The big asset buy in the healthcare industry provided a healthy pop to the two companies involved on Thursday. The stock price of the buyer, sector mainstay AbbVie (NYSE: ABBV), enjoyed a nearly 3%

AbbVie Should Consider a Dividend Cut -- Here's Why: https://g.foolcdn.com/editorial/images/756473/biotech-researcher.jpg
AbbVie Should Consider a Dividend Cut -- Here's Why

Since its split from Abbott Laboratories in 2013, AbbVie (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the

Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?: https://g.foolcdn.com/editorial/images/756106/time-to-buy.jpg
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?

Pfizer's (NYSE: PFE) stock performance has been disappointing this year (down 38%). The company has faced multiple challenges, such as declining revenues from COVID-19 products, looming patent

Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?: https://g.foolcdn.com/editorial/images/756106/time-to-buy.jpg
Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?

Pfizer's (NYSE: PFE) stock performance has been disappointing this year (down 38%). The company has faced multiple challenges, such as declining revenues from COVID-19 products, looming patent

3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later: https://g.foolcdn.com/editorial/images/755957/retired-woman-investing-laptop-401k-ira.jpg
3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later

Are you a pro when it comes to procrastination? Some investors take so long to make a decision on buying stocks that they miss out on great upside moves. And when those stocks pay juicy dividends

2 Healthcare Stocks That Could Help Set You Up for Life: https://g.foolcdn.com/editorial/images/755812/physician-giving-medicine-to-elderly-patient.jpg
2 Healthcare Stocks That Could Help Set You Up for Life

Some investors intend to hold shares of the companies they own for good, never having to sell them. This strategy makes sense. Warren Buffett, the man widely regarded as the greatest contemporary

2 Healthcare Stocks That Could Help Set You Up for Life: https://g.foolcdn.com/editorial/images/755812/physician-giving-medicine-to-elderly-patient.jpg
2 Healthcare Stocks That Could Help Set You Up for Life

Some investors intend to hold shares of the companies they own for good, never having to sell them. This strategy makes sense. Warren Buffett, the man widely regarded as the greatest contemporary

2 Healthcare Stocks That Could Help Set You Up for Life: https://g.foolcdn.com/editorial/images/755812/physician-giving-medicine-to-elderly-patient.jpg
2 Healthcare Stocks That Could Help Set You Up for Life

Some investors intend to hold shares of the companies they own for good, never having to sell them. This strategy makes sense. Warren Buffett, the man widely regarded as the greatest contemporary

Could AbbVie Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/755576/a-group-of-scientists-looking-at-a-report.jpg
Could AbbVie Stock Help You Become a Millionaire?

If you want an investment to make you a millionaire, you need three things. The first is some decent money to invest in the stock market, ideally at least $20,000. The second is time and patience --

Is Pfizer Stock a Buy Now?: https://g.foolcdn.com/editorial/images/755825/pharmacist-talking-to-patient.jpg
Is Pfizer Stock a Buy Now?

Last year, pharmaceutical giant Pfizer (NYSE: PFE) reported the highest revenue it had ever had in a single calendar year. But in 2023, the drugmaker has substantially underperformed the market, and

Is Pfizer Stock a Buy Now?: https://g.foolcdn.com/editorial/images/755825/pharmacist-talking-to-patient.jpg
Is Pfizer Stock a Buy Now?

Last year, pharmaceutical giant Pfizer (NYSE: PFE) reported the highest revenue it had ever had in a single calendar year. But in 2023, the drugmaker has substantially underperformed the market, and

Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?: https://g.foolcdn.com/editorial/images/755561/a-rich-person-counting-money.jpg
Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?

A dividend yield can tell you a lot about a payout. Not only does it tell you how much you could be collecting in dividend income, but it can give you an indication of investor sentiment, and

EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction